Phospho-EIF4B (Ser422) Recombinant antibody

Phospho-EIF4B (Ser422) Recombinant Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human

Applications

WB, ELISA

Conjugate

Unconjugated

CloneNo.

1K3

Cat no : 82550-1-RR

Synonyms

EIF 4B, EIF4B, Phospho-EIF4B (Ser422), PRO1843

---

Validation Data Gallery

• 

  WB analysis using 82550-1-RR

  Non-treated and Calyculin A treated HeLa cells were subjected to SDS PAGE followed by western blot with 82550-1-RR (Phospho-EIF4B (Ser422) antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Beta Actin antibody as loading control.

---

Tested Applications

• Positive WB detected in: Calyculin A treated HeLa cells, HeLa cells

Recommended dilution

• Western Blot (WB): WB : 1:2000-1:10000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

82550-1-RR targets Phospho-EIF4B (Ser422) in WB, ELISA applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: Peptide
• Full Name: eukaryotic translation initiation factor 4B
• Calculated Molecular Weight: 611 aa, 69 kDa
• Observed Molecular Weight: 70-80 kDa
• GenBank Accession Number: BC073154
• Gene Symbol: EIF4B
• Gene ID (NCBI): 1975
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

EIF4B is one of the mammalian eukaryotic initiation factors (eIF) that are required for the ATP-dependent binding of mRNA to the 40 S ribosomal subunit, and the other EIF proteins are EIF4A, EIF4F. EIF4B is involved in translation of numerous proliferative or anti-apoptotic mRNAs with highly structured 5'UTR and subsequently affect cell growth and survival. It was reported that false expression and phosphorylation levels of EIF4B are involved in several tumors including breast cancer, cell lymphoblastic leukemia and diffuse large B-cell lymphoma (PMID: 26848623). Ser422 is regarded as the major modification site of EIF4B that is phosphorylated in response to amino-acid refeeding(PMID: 22750809).